LEADER 00000nam  2200373 a 4500 
001    AH21639446 
003    StDuBDS 
005    20111202104146.0 
007    cr|||||||||||| 
008    110217s2011    enka    sb    001 0 eng d 
020    9781444342543 (e-book) 
040    DNLM/DLC|cDLC|dUk|dStDuBDSZ|dUkPrAHLS 
050  0 RC862.I53|bC553 2011 
082 00 616.344|222 
245 00 Clinical dilemmas in inflammatory bowel disease
       |h[electronic resource] :|bnew challenges /|cedited by 
       Peter M. Irving ... [et al.]. 
250    2nd ed. 
260    Chichester :|bWiley-Blackwell,|c2011. 
300    xv, 268 p. :|bill. 
505 0  Contents: List of Contributors. Preface. Part 1: Genes and
       Phenotype in IBD. 1 Which will take us further in IBD - 
       study of coding variation or epigenetics? ( Miles Parkes 
       ). 2 IBD in different ethnic groups: same or different? ( 
       Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. 
       Selinger ). Part 2: Bugs and IBD - good, bad or 
       indifferent? 3 How does the risk of infection influence 
       management of IBD around the world? ( Kiran K. Peddi and 
       Ian Craig Lawrance ). 4 Travelling with IBD ( Ing Shian 
       Soon and Gilaad Kaplan ). 5 What to do about hepatitis B 
       and hepatitis C in patients with IBD ( Morven Cunningham 
       and Graham R. Foster ). 6 CMV in IBD - passenger or 
       pathogen? ( Ahmed Kandiel & Bret Lashner ). 7 Clostridium 
       difficile in IBD: Impact, Prevention and Treatment ( 
       Ashwin N. Ananthakrishnan and David G. Binion ). 8 Pre- 
       and synbiotics: placebo or panacea ( James O. Lindsay ). 9
       Worms - light at the end of their burrow? ( John Leung and
       Joel V. Weinstock ). 10 Do we really need to vaccinate all
       patients with IBD? ( Gauree Gupta and Gil Y. Melmed ). 
       Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or 
       marvel? ( Richard B. Gearry, Andrew S. Day ). 12 Radiation
       exposure in IBD: how do we minimize the dangers? ( Owen J 
       O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. 
       Maher ). 13 Surveillance colonoscopy in UC - what's the 
       best way to do it? ( Matt Rutter ). Part 4: Medical 
       therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride 
       forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? (
       Richard Logan and Venkataraman Subramanian ). 16 Why do we
       still use 5-ASAs in Crohns disease? ( Stephen Hanauer, 
       Henit Yanai, Emma Calabrese ). Steroids. 17 Steroids in 
       Crohn's disease: do the benefits outweigh the dangers? ( 
       A. Hillary Steinhart ). Immunomodulators. 18 Thioguanine 
       nucleotide measurement: Non-adherent, shunter, under-dosed
       or resistant? ( Miles Sparrow ). 19 Thiopurines and the 
       sun: what should be done? ( Conal M. Perrett, Jane M. 
       McGregor, Catherine A. Harwood ). 20 Do thiopurines worsen
       risk and prognosis of cervical neoplasia? ( Jeremy D. 
       Sanderson and Melissa A. Smith ). 21 Optimising use of 
       methotrexate ( Anna Foley and Peter R. Gibson ). 22 Which 
       calcineurin inhibitor and when? ( A. Barney Hawthorne ). 
       Biologics. 23 Are all anti-TNF agents the same? ( Jennifer
       L. Jones ). 24 One drug or two: Do patients on biologics 
       need concurrent immunomodulation? ( Glen A. Doherty and 
       Adam S. Cheifetz ). 25 How do we identify patients needing
       early aggressive therapy and what should we use? ( Marc 
       Ferrante and Severine Vermeire ). 26 What is the role of 
       biologics in UC? ( Joanna K. Law and Brian Bressler ). 27 
       What can we do with Crohn's patients refractory to antiTNF
       therapy? ( David T. Rubin ). 28 Which EIMs respond to 
       biologics? ( Tina A. Mehta and CS Probert ). 29 Use and 
       abuse of biologics in pregnancy ( Marla C. Dubinsky ). 30 
       Is anti-TNF therapy safe to use in people with a history 
       of malignancy? ( Mark Lust and Simon Travis ). 31 What and
       how should we tell patients about the risks of 
       immunomodulators and biologics? ( Corey A Siegel ). 32 
       When, how and in whom should we stop biologics? ( Edouard 
       Louis, Jacques Belaiche, Catherine Reenaers ). Part 5: 
       Other treatments. 33 Avoiding drug interactions ( Tim 
       Elliott and Peter M. Irving ). 34 Is there still a role 
       for ursodeoxycholic acid treatment in patients with 
       inflammatory bowel disease associated with primary 
       sclerosing cholangitis? ( Emmanouil Sinakos & Keith Lindor
       ). 35 Stem cell transplantation for Crohn's: what's the 
       risk-benefit ratio? ( Venkataraman Subramanian and 
       Christopher J Hawkey ). 36 Complementary Therapy: Is There
       a Needle in the Haystack? ( Shane M. Devlin ). Part 6: 
       Surgical Dilemmas in IBD. 37 Optimising IBD patients for 
       surgery and recovery ( Jonathan Wilson and Alastair 
       Windsor ). 38 Is surgery the best initial treatment for 
       limited ileocaecal Crohn's disease? ( Tom Oresland ). 39 
       Laparoscopic or open surgery for IBD? ( Donna Appleton and
       Michael Hershman ). 40 Perianal Crohn's disease - optimal 
       management ( David A. Schwartz and Norman R. Clark III ). 
       41 Does anti-TNF therapy increase the risk of 
       Complications of surgery? ( Ming Valerie Lin, Wojciech 
       Blonski and Gary R. Lichtenstein ). 42 Pouches for 
       Indeterminate Colitis and Crohn's Disease: Act Now, Pay 
       Later? ( Phillip Fleshner ). 43 Dealing with pouchitis ( 
       Bo Shen and Simon McLaughlin ). Part 7: Unsolved issues in
       IBD. 44 Mucosal healing in IBD - does it matter? ( Geert 
       D'Haens ). 45 Vitamin D in IBD: from genetics to bone 
       health via cancer and immunology ( Helen M. Pappa and 
       Richard J. Grand ). 46 Got Milk? Medication Use and 
       Nursing in Women with IBD (Sunanda Kane). 47 Does stress 
       matter? ( Robert Maunder ). 48 IBS is common in IBD: fact 
       or fallacy? ( James Goodhand & David Rampton ). 49 So 
       where is all the cancer? ( Judith E. Baars & C. Janneke 
       van der Woude ). Part 8: Nutrition in IBD. 50 What should 
       patients with IBD eat? ( Emile Richman, Keith Leiper, 
       Jonathan Rhodes ). 51 Enteral Nutrition in Crohn's - Who 
       for, When, How and Which Formula? ( R. Shamir and Ernest 
       G. Seidman ). 52 Optimizing treatment of iron deficiency 
       anemia ( Hermann Schulze and Axel Dignass ). Part 9: 
       Management process. 53 IBD Standards: will they enhance 
       patient care? ( Michael D. Kappelman ). 54 Your treatment 
       won't work if the patient doesn't take it ( Rob Horne ). 
       55 Inflammatory Bowel Disease: What to tell your ED team (
       Louise Langmead ). 56 Transitioning from pediatric to 
       adult care ( Elizabeth J. Hait and Laurie N. Fishman ). 57
       Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) 
       Care ( William J. Tremaine ). 
506 1  400 annual accesses.|5UkHlHU 
650  0 Inflammatory bowel diseases. 
650  0 Inflammatory bowel diseases|xDecision making. 
700 1  Irving, Peter,|d1970- 
856 40 |uhttp://www.vlebooks.com/vleweb/product/
       openreader?id=Hull&isbn=9781444342543|zGo to ebook 
936    Askews